Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $28.31 USD
Change Today +0.45 / 1.62%
Volume 196.3K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2929 Seventh Street

Suite 100

Berkeley, CA 94710

United States

Phone: 510-848-5100

Fax: 510-848-1327

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics using toll-like receptor (TLR) biology. The company’s development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. HEPLISAV-B The company’s main vaccine product candidate is HEPLISAV-B (previously known as HEPLISAV), an investigational adult hepatitis B vaccine in Phase 3 clinical development. HEPLISAV-B combines 1018, a proprietary TLR9 agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg or HBsAg) manufactured at its wholly-owned subsidiary in Düsseldorf, Germany (Rhein or Dynavax Europe). In 2014, the company initiated HBV-23, a Phase 3 observer-blinded, randomized, active-controlled, multicenter trial of the safety and immunogenicity of HEPLISAV-B. Cancer Immunotherapy The company’s main cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Two Phase 1 clinical studies of SD-101 have been completed, establishing that it is safe and well-tolerated at a range of doses far exceeding the expected therapeutic level for oncology uses. Autoimmune and Inflammatory Diseases The company also has clinical and preclinical programs focused on therapeutics for autoimmune and inflammatory diseases. AZD1419 for Asthma: The company’s most advanced inflammatory disease candidate is AZD1419, which is partnered with AstraZeneca AB (AstraZeneca). AZD1419 is designed to change the basic immune response to environmental allergens, such as house dust and pollens, to prolonged reduction in asthma symptoms by converting the response from one primarily mediated by type-2 helper T cells (Th2) to type-1 helper T cells (Th1). Intellectual Property As of December 31, 2014, the company’s intellectual property portfolio included approximately 30 issued U.S. patents, 250 issued or granted foreign patents, and 50 additional pending U.S. and foreign patent applications claiming compositions and formulations of TLR agonist and inhibitors, their methods of use or processes for their manufacture. The company also has exclusive licenses under two agreements to several patents and applications owned by the Regents of the University of California. Research and Development The company’s research and development expenses included $84.6 million, as of December 31, 2014. Regulations The company and all of its contract manufacturers are required to comply with the applicable FDA or foreign regulatory agency current Good Manufacturing Practices regulations. History The company was founded in 1996. It was incorporated in California in August 1996. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was reincorporated in Delaware in 2000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $28.31 USD +0.45

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $13.60 USD +0.20
Celldex Therapeutics Inc $14.13 USD +0.20
Genocea Biosciences Inc $10.99 USD +0.05
Inovio Pharmaceuticals Inc $7.11 USD +0.02
ZIOPHARM Oncology Inc $9.02 USD +0.30
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 122.7x
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 145.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.